Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Oncology
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective
Tobias Engel Ayer Botrela CIOP – Centro Integrado de Oncologia e Pesquisa, Poços de Caldas, Brazil
https://orcid.org/0000-0001-9137-0637
https://orcid.org/0000-0001-9137-0637, , , Cássia Rita Pereira da Veigab MSD Brasil, São Paulo, Brazil;c Department of General and Applied Administration, Universidade Federal do Paraná, Curitiba, BrazilCorrespondence[email protected]
https://orcid.org/0000-0002-9219-6279
https://orcid.org/0000-0002-9219-6279, & Denis Leonardo Jardimd Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazilhttps://orcid.org/0000-0003-4663-1521
https://orcid.org/0000-0003-4663-1521